Illumina, Inc. (ILMN)
Unlocking Q1 Potential of Illumina (ILMN): Exploring Wall Street Estimates for Key Metrics
Looking beyond Wall Street's top-and-bottom-line estimate forecasts for Illumina (ILMN), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended March 2026.
Illumina (ILMN) Reports Next Week: Wall Street Expects Earnings Growth
Illumina (ILMN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.
Illumina: Competitive Threats Priced In
Illumina fundamentals are improving, with FY26 expected to return to positive growth and enable operating leverage. Competition from Roche and others is a risk, but recent news appears priced in; shares have stabilized since the Roche Axelios reveal. FY26 guidance calls for 2% organic growth, EBIT margin expansion of 3% YoY, and further upside from the Somalogic acquisition.
Illumina (ILMN) is a Top-Ranked Momentum Stock: Should You Buy?
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Here's Why Illumina (ILMN) is a Strong Growth Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
ILMN Stock Gains Following Expanded Collaboration With Labcorp
Illumina gains after expanding Labcorp collaboration to boost NGS oncology adoption, broaden testing access, and drive growth in precision cancer care.
Bamco Inc. NY Sells 39,378 Shares of Illumina, Inc. $ILMN
Bamco Inc. NY reduced its holdings in shares of Illumina, Inc. (NASDAQ: ILMN) by 15.9% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 208,094 shares of the life sciences company's stock after selling 39,378 shares during the period.
Illumina Stock Climbs 44.8% in a Year: What's Driving the Rally?
ILMN stock surges 44.8% in a year, fueled by NovaSeq X sequencing demand, broader NGS testing adoption, multiomics expansion and improving margins.
Here's Why Illumina (ILMN) is a Strong Momentum Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Here's Why Illumina (ILMN) is a Strong Value Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Why Illumina (ILMN) is a Top Growth Stock for the Long-Term
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
